Where Will Moderna Be in 1 Year?

All eyes are on drug manufacturers in 2020 as they race to develop the first coronavirus vaccine. Globally, recorded cases of COVID-19 have surpassed 25 million, with at least 847,000 related deaths worldwide. More than 6 million cases have been reported in the U.S. alone, with at least 183,000 deaths as of Aug. 30.

According to the World Health Organization, there are more than 150 novel coronavirus vaccine candidates in development now, with nearly 30 of them in clinical testing. U.S.-based Moderna (NASDAQ: MRNA) reported positive results from the phase 1 trial for its COVID-19 mRNA vaccine in July, and started the phase 3 trial on July 27. It's no surprise that its stock is up 245% year to date, while the S&P 500 has risen just 9%.

But what will happen to Moderna if its late-stage trials aren't successful, or if regulatory approvals for its potential vaccine pose some challenge? Even if it is successful, what does the next year look like for the company?

Continue reading

Source Fool.com